10-Q: Aclarion Inc. Reports Third Quarter 2024 Results Amidst Financial Challenges

Aclarion Inc.'s Q3 2024 results show a decrease in revenue and ongoing losses, alongside efforts to address financial and compliance issues.

Summary

• Aclarion Inc. reported a net loss of $1.378 million for the third quarter of 2024, compared to a net loss of $998,010 for the same period in 2023.
• The company's revenue decreased to $14,407 in Q3 2024 from $19,065 in Q3 2023, primarily due to the conclusion of certain clinical activities.
• Operating expenses totaled $1.289 million for the quarter, with general and administrative expenses being the largest component at $860,461.
• For the nine months ended September 30, 2024, the net loss was $5.015 million, compared to $3.646 million for the same period in 2023.
• The company's revenue for the first nine months of 2024 was $35,492, a decrease from $61,607 in the same period of 2023.
• Aclarion is facing challenges with Nasdaq listing requirements, including minimum bid price and stockholders' equity requirements.
• The company has received an extension until January 31, 2025, to demonstrate compliance with Nasdaq listing rules.
• A reverse stock split is planned to assist with compliance with the minimum bid price requirement.
• The company believes that recent capital raises will fund operations into December 2024, but additional funding will be required.

Sentiment

Score: 3

Explanation: The document indicates significant financial challenges, including declining revenue, increasing losses, and potential delisting from Nasdaq. While the company has taken steps to raise capital and address compliance issues, the overall outlook is negative due to the uncertainty surrounding its ability to continue as a going concern.

Positives

• The company has secured an extension from Nasdaq until January 31, 2025, to regain compliance with listing requirements.
• Aclarion has successfully raised capital through a public offering, an equity line, and the issuance of preferred stock.
• The company is actively working to improve internal controls over financial reporting.
• The company has reduced some operating expenses, including personnel and D&O insurance premiums.
• The company has retired some debt through equity exchanges.

Negatives

• Aclarion experienced a significant decrease in revenue for both the quarter and the nine-month period.
• The company's net losses have increased compared to the same periods in the previous year.
• Aclarion is facing delisting from Nasdaq due to non-compliance with minimum bid price and stockholders' equity requirements.
• The company's cash position is limited, and additional funding is needed beyond December 2024.
• The company has identified material weaknesses in its internal control over financial reporting.

Risks

• The company's ability to continue as a going concern is uncertain due to recurring losses and the need for additional financing.
• Failure to regain compliance with Nasdaq listing requirements could result in delisting.
• The company's limited operating history and dependence on key personnel pose risks.
• The company faces competition from other companies in the healthcare technology sector.
• The company's ability to develop and commercialize its products is subject to significant uncertainties.
• The company's financial results are subject to estimates and assumptions that may prove to be incorrect.
• The company's internal controls over financial reporting are not effective.

Future Outlook

The company believes that the net proceeds from recent capital raises will be sufficient to fund current operating plans into December 2024, but additional funding will be required to continue technology development. The company intends to implement a reverse stock split to assist with compliance with Nasdaq listing rules.

Management Comments

• Management plans to secure additional funding to continue technology development.
• Management is evaluating available options to resolve the deficiency and regain compliance with the Nasdaq minimum stockholders equity requirement.

Industry Context

Aclarion operates in the healthcare technology sector, which is characterized by high research and development costs, long development cycles, and regulatory hurdles. The company's financial challenges and need for additional funding are not uncommon in this industry, particularly for early-stage companies. The company's focus on magnetic resonance spectroscopy (MRS) and proprietary biomarkers positions it within the diagnostic imaging and personalized medicine sub-sectors, which are experiencing growth but also intense competition.

Comparison to Industry Standards

• Aclarion's revenue of $35,492 for the first nine months of 2024 is significantly lower than that of comparable medical technology companies at a similar stage of development. For example, companies like Butterfly Network (BFLY) and Nano-X Imaging (NNOX), which are also developing innovative medical imaging technologies, have reported revenues in the millions of dollars during similar periods.
• The company's net loss of $5.015 million for the first nine months of 2024 is also higher than some of its peers. While many early-stage medical technology companies operate at a loss, Aclarion's losses are substantial relative to its revenue base. Companies like Senseonics (SENS) and InMode (INMD), which are further along in their commercialization efforts, have shown a path to profitability or reduced losses.
• Aclarion's reliance on external funding and its current financial position are similar to many early-stage medical device companies. However, the company's challenges with Nasdaq listing requirements and internal controls raise concerns about its operational and financial stability. Companies like Guardant Health (GH) and Exact Sciences (EXAS), which have successfully navigated the public markets, have demonstrated stronger financial controls and compliance practices.
• The company's planned reverse stock split is a common strategy for companies facing delisting due to low share prices. However, it is not a long-term solution and does not address the underlying issues of revenue generation and profitability. Companies like Cassava Sciences (SAVA) and Amylyx Pharmaceuticals (AMLX), which have also faced share price volatility, have focused on clinical trial progress and commercialization to improve investor confidence.

Corporate Governance

Related Party Transactions

• In February 2023, the company sold one share of Series A preferred stock to Jeffrey Thramann, the company's Executive Chairman, for $1,000. This share was later redeemed for the same amount.

Stakeholder Impact

• Shareholders face the risk of further dilution and potential loss of investment due to the company's financial challenges and potential delisting.
• Employees may experience uncertainty due to the company's financial instability and potential restructuring.
• Customers may be concerned about the company's ability to continue providing its services.
• Suppliers and creditors may face increased risk of non-payment due to the company's financial difficulties.

Next Steps

• The company intends to implement a reverse stock split to assist with compliance with Nasdaq's minimum bid price requirement.
• The company needs to secure additional funding to continue its technology development.
• The company must demonstrate compliance with Nasdaq listing rules by January 31, 2025.
• The company will continue to work with an outside firm to improve internal controls over financial reporting.

Key Dates

Keywords

Aclarion, NOCISCAN, financial results, Nasdaq, delisting, reverse stock split, preferred stock, equity line, revenue, net loss, internal controls, going concern